Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Sell
27
NVO Quote, Financials, Valuation and Earnings
Last price:
$48.02
Seasonality move
:
5.86%
Day range:
$47.30 - $48.11
52-week range:
$43.08 - $112.52
Dividend yield:
3.63%
P/E ratio:
13.86x
P/S ratio:
4.54x
P/B ratio:
10.43x
Volume:
11.5M
Avg. volume:
19.9M
1-year change:
-56.44%
Market cap:
$211.4B
Revenue:
$42.1B
EPS (TTM):
$3.43
Analysts' Opinion
-
Consensus RatingNovo Nordisk A/S has received a consensus rating of Buy. The company's average rating is a Buy based on 6 Buy ratings, 3 Hold ratings, and 2 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $53.05, Novo Nordisk A/S has an estimated upside of 11.52% from its current price of $47.57.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $41.97 representing 11.78% downside risk from its current price of $47.57.
Fair Value
-
According to the consensus of 11 analysts, Novo Nordisk A/S has 11.52% upside to fair value with a price target of $53.05 per share.
NVO vs. S&P 500
-
Over the past 5 trading days, Novo Nordisk A/S has overperformed the S&P 500 by 1.07% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Novo Nordisk A/S does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Novo Nordisk A/S has grown year-over-year revenues for 21 quarters straight. In the most recent quarter Novo Nordisk A/S reported revenues of $11.7B.
Earnings Growth
-
Novo Nordisk A/S earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Novo Nordisk A/S reported earnings per share of $0.70.
Enterprise value:
222.2B
EV / Invested capital:
5.21x
Price / LTM sales:
4.54x
EV / EBIT:
11.22x
EV / Revenue:
4.76x
PEG ratio (5yr expected):
1.22x
EV / Free cash flow:
24.03x
Price / Operating cash flow:
22.92x
Enterprise value / EBITDA:
9.65x
Gross Profit (TTM):
$38.3B
Return On Assets:
21.76%
Net Income Margin (TTM):
32.76%
Return On Equity:
68.76%
Return On Invested Capital:
41.85%
Operating Margin:
31.74%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $30.8B | $39.3B | $46.7B | $10.5B | $11.7B | |
| Gross Profit | $25.9B | $33.3B | $38.3B | $8.8B | $8.9B | |
| Operating Income | $13.3B | $17.3B | $19.8B | $5B | $3.7B | |
| EBITDA | $14.5B | $19.7B | $23B | $5.3B | $4.9B | |
| Diluted EPS | $2.41 | $3.08 | $3.43 | $0.90 | $0.70 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $14.2B | $15.7B | $20.2B | $29.2B | $28.6B | |
| Total Assets | $27.1B | $32B | $42.6B | $59.5B | $80.6B | |
| Current Liabilities | $13.8B | $17.2B | $24.5B | $31.2B | $36.9B | |
| Total Liabilities | $16.8B | $21.9B | $29.4B | $41.5B | $53.9B | |
| Total Equity | $10.3B | $10.1B | $13.2B | $18B | $26.7B | |
| Total Debt | $2.1B | $3.2B | $2.8B | $7.7B | $14B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $15.3B | $17.2B | $18.7B | $6.4B | $7.3B | |
| Cash From Investing | -$6.2B | -$7.6B | -$18.8B | -$3.1B | -$2.4B | |
| Cash From Financing | -$8.7B | -$5.6B | -$3.4B | -$2.7B | -$2.8B | |
| Free Cash Flow | $11.1B | $9.8B | $9.2B | $4.6B | $4.8B | |
NVO
Sector
Market Cap
$211.4B
$28.4M
Price % of 52-Week High
42.28%
50.35%
Dividend Yield
3.63%
0%
Shareholder Yield
5.06%
-1.32%
1-Year Price Total Return
-56.44%
-22.19%
Beta (5-Year)
0.670
0.521
Dividend yield:
3.63%
Annualized payout:
$1.45
Payout ratio:
--
Growth streak:
5 years
Technicals
8-day SMA
Sell
Level
$47.64
200-day SMA
Sell
Level
$63.28
Bollinger Bands (100)
Sell
Level
48.46 - 60.6
Chaikin Money Flow
Buy
Level
1.9B
20-day SMA
Sell
Level
$47.86
Relative Strength Index (RSI14)
Sell
Level
43.87
ADX Line
Sell
Level
17.59
Williams %R
Neutral
Level
-35.9486
50-day SMA
Sell
Level
$52.29
MACD (12, 26)
Sell
Level
-1.12
25-day Aroon Oscillator
Sell
Level
-72
On Balance Volume
Neutral
Level
1.6B
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (7.0926)
Buy
CA Score
(Annual)
Level (0.6478)
Buy
Beneish M-Score
(Annual)
Level (-2.5103)
Sell
Momentum Score
Level (2)
Buy
Ohlson Score
Level (-1.1185)
Buy
Piotroski F Score
(Annual)
Level (5)
Buy
Quality Ratio Score
Level (9)
Buy
Fundamental Score
Level (9)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.
Stock Forecast FAQ
In the current month, NVO has received 6 Buy ratings 3 Hold ratings, and 2 Sell ratings. The NVO average analyst price target in the past 3 months is $53.05.
-
Where Will Novo Nordisk A/S Stock Be In 1 Year?
According to analysts, the consensus estimate is that Novo Nordisk A/S share price will rise to $53.05 per share over the next 12 months.
-
What Do Analysts Say About Novo Nordisk A/S?
Analysts are divided on their view about Novo Nordisk A/S share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Novo Nordisk A/S is a Sell and believe this share price will drop from its current level to $41.97.
-
What Is Novo Nordisk A/S's Price Target?
The price target for Novo Nordisk A/S over the next 1-year time period is forecast to be $53.05 according to 11 Wall Street analysts, 6 of them rate the stock a Buy, 2 rate the stock a Sell, and 3 analysts rate the stock a Hold.
-
Is NVO A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Novo Nordisk A/S is a Buy. 6 of 11 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of NVO?
You can purchase shares of Novo Nordisk A/S via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Novo Nordisk A/S shares.
-
What Is The Novo Nordisk A/S Share Price Today?
Novo Nordisk A/S was last trading at $48.02 per share. This represents the most recent stock quote for Novo Nordisk A/S. Yesterday, Novo Nordisk A/S closed at $47.57 per share.
-
How To Buy Novo Nordisk A/S Stock Online?
In order to purchase Novo Nordisk A/S stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get NVO Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
NVO
Sector
P/E ratio
13.86x
23.66x
PEG ratio
1.22x
-0.01x
P/B ratio
10.43x
1.84x
Price / LTM sales
4.54x
1.60x
Growth Metrics
NVO
Sector
Revenue growth
11.8%
4.85%
Earnings growth
-21.84%
11.15%
Revenue (5-year growth)
18.15%
6.45%
Earnings forecast
$0.66
-$0.20
Profitability
NVO
Sector
Profitability FY 2024
$35.3B
$3.6M
Return on invested capital
41.85%
-30.98%
Return on assets
21.76%
-27.62%
Return on equity
68.76%
-36.69%
Earnings Date
Last Earnings Date
Nov
5
Next Earnings Date
Feb
4
Estimated Next Earnings Date
Feb
4
Balance Sheet
NVO
Sector
Total cash
$5.1B
$27.2M
Short term investments
$1.5B
$25.7M
Total assets
$64.7B
$79.9M
Long term debt
$14B
$4.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Buy
51
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 61x
Buy
65
Is AAPL Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 38x
Buy
69
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Sell
47
PSTG alert for Dec 4
Pure Storage, Inc. [PSTG] is up 5.05% over the past day.
Sell
41
SMX alert for Dec 4
SMX (Security Matters) Plc [SMX] is up 154.74% over the past day.
Sell
43
HY alert for Dec 4
Hyster-Yale, Inc. [HY] is up 1.92% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
